Welcome to our dedicated page for Arteris SEC filings (Ticker: AIP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Arteris, Inc. filings document a semiconductor technology business built around System IP for SoC and chiplet design. Its 8-K reports cover quarterly and annual operating results, financial-condition updates, guidance exhibits, customer shipment milestones, royalty trends and product portfolio disclosures for network-on-chip interconnect IP, SoC integration automation software and hardware security assurance.
The company’s proxy materials cover board elections, executive compensation, equity incentive arrangements and stockholder voting matters. They also describe governance and business context for Arteris’ markets, including automotive, artificial intelligence and machine learning, 5G communications, data centers, edge computing, enterprise and consumer electronics.
Morgan Stanley Smith Barney LLC submitted a Form 144 notice for the proposed resale of 20,000 Common shares related to an Nasdaq‑traded issuer, dated 03/09/2026.
The filing lists recent 10b5-1 brokered sales by related holders in the prior three months, including sales by BAYVIEW LEGACY, LLC of 50,000 shares on 01/08/2026 (proceeds $829,155.00) and 47,244 shares on 02/09/2026 (proceeds $718,359.19).
Arteris, Inc. director Saiyed Atiq Raza reported open‑market sales of 109,721 shares of common stock by the Saiyed Atiq Raza and Nandini Saraiya 2012 Revocable Trust. The trust sold 106,031 shares on March 2, 2026 at a weighted average price of $17.2127 and 3,690 shares on March 4, 2026 at a weighted average price of $17.0153, under a pre‑arranged Rule 10b5‑1 trading plan.
After these transactions, the trust held 390,000 shares indirectly, and Raza also held 20,839 shares directly.
AIP reported sale notices and related 10b5-1 transactions. The filing lists an issuer notice to sell 90,000 common shares from previously exercised stock options dated 12/28/2020, and discloses 10b5-1 sales of common shares on 02/25/2026, 02/26/2026, and 02/27/2026.
The excerpt shows executed 10b5-1 trades of 4,907, 73,610, and 11,762 common shares (totaling 90,279 shares) with reported proceeds in dollars. Shares outstanding are listed as 45,467,261 as of 03/02/2026.
Arteris, Inc. director-related entity activity shows the Saiyed Atiq Raza and Nandini Saraiya 2012 Revocable Trust selling a total of 90,279 shares of common stock in open-market transactions. These sales occurred on February 25–27, 2026 at weighted average prices around $17 per share under a pre-arranged Rule 10b5-1 trading plan.
After these indirect sales, the trust held 499,721 shares, while a separate direct holding for the reporting person stood at 20,839 shares of Arteris common stock as of February 25, 2026.
AIP reports a Form 144 notice to sell 110,000 common shares. The filing lists a broker (Morgan Stanley Smith Barney LLC) and references NASDAQ with a filing date of 02/25/2026. It cites two lots from prior option exercises: 65,000 (04/13/2015) and 45,000 (12/28/2020).
Arteris, Inc. major shareholder Bayview Legacy, LLC, a 10% owner, reported a bona fide gift transfer of 70,000 shares of Common Stock on February 20, 2026. Following this non-cash disposition, Bayview Legacy, LLC indirectly holds 9,279,071 Arteris shares, with voting and dispositive power exercised by its manager, K. Charles Janac.
Moll Laurent R reported acquisition or exercise transactions in this Form 4 filing.
Arteris, Inc. Chief Operating Officer Laurent R. Moll received an equity award of 37,553 shares of common stock on a grant or award basis, at a stated price of $0.0000 per share. After this award, his directly owned common stock holdings total 288,126 shares.
The footnote clarifies that the 37,553 shares are in the form of restricted stock units, each representing a contingent right to one share of common stock. These RSUs will vest as to 1/16 of the total on 4/1/2026, with the remainder vesting in equal quarterly installments thereafter, and they have no expiration date.
Arteris, Inc. reported that its VP and Chief Financial Officer, Nicholas B. Hawkins, acquired 41,217 restricted stock units as an equity award. Each RSU represents one share of common stock and vests 1/16 on 4/1/2026, then in equal quarterly installments. Following this grant, he holds 123,484 shares of common stock in total.
Alpern Paul L reported acquisition or exercise transactions in this Form 4 filing.
Arteris, Inc. reported that its VP and General Counsel, Paul L. Alpern, received an equity award of 32,385 restricted stock units (RSUs), each representing one share of common stock, at no cash cost per share. These RSUs will vest as to 1/16 of the total on April 1, 2026, then in equal quarterly installments thereafter, and have no expiration date. Following this grant, Alpern beneficially owns 90,035 shares of common stock, including the 32,385 RSUs.